Standardized incidence ratio (SIR) of malignancy by site during the followup period.
| Site | Total, n = 5573 | Male, n = 1031 | Female, n = 4542 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | SIR | 95% CI | n | SIR | 95% CI | n | SIR | 95% CI | |
| All sites | 117 | 0.79 | 0.66 to 0.95 | 35 | 0.85 | 0.61 to 1.18 | 82 | 0.98 | 0.79 to 1.21 |
| Oral cavity and pharynx | 4 | 1.26 | 0.47 to 3.35 | 2 | 2.00 | 0.50 to 7.99 | 2 | 1.72 | 0.43 to 6.88 |
| Esophagus | 3 | 0.61 | 0.20 to 1.90 | 2 | 1.11 | 0.28 to 4.45 | 1 | 0.99 | 0.14 to 7.04 |
| Stomach | 19 | 0.77 | 0.49 to 1.21 | 8 | 1.04 | 0.52 to 2.08 | 11 | 1.10 | 0.61 to 1.98 |
| Colon/rectum | 8 | 0.30 | 0.15 to 0.59 | 3 | 0.41 | 0.13 to 1.27 | 5 | 0.34 | 0.14 to 0.81 |
| Liver | 2 | 0.20 | 0.05 to 0.80 | 0 | — | — | 2 | 0.46 | 0.11 to 1.82 |
| Gallbladder and bile ducts | 3 | 0.84 | 0.27 to 2.60 | 0 | — | — | 3 | 1.34 | 0.43 to 4.17 |
| Pancreas | 3 | 0.54 | 0.17 to 1.66 | 1 | 0.69 | 0.10 to 4.92 | 2 | 0.60 | 0.15 to 2.39 |
| Lung, trachea | 15 | 0.80 | 0.48 to 1.32 | 8 | 1.35 | 0.67 to 2.70 | 7 | 0.87 | 0.41 to 1.82 |
| Skin | 4 | 1.44 | 0.54 to 3.84 | 1 | 1.48 | 0.21 to 10.51 | 3 | 1.63 | 0.53 to 5.06 |
| Breast | 17 | 0.76 | 0.48 to 1.20 | 0 | — | — | 17 | 0.93 | 0.59 to 1.47 |
| Cervix uteri | 1 | — | — | — | — | — | 1 | 0.26 | 0.04 to 1.87 |
| Corpus uteri | 4 | — | — | — | — | — | 4 | 1.17 | 0.44 to 3.12 |
| Ovary | 2 | — | — | — | — | — | 2 | 0.78 | 0.20 to 3.12 |
| Prostate | 7 | — | — | 7 | 1.40 | 0.67 to 2.93 | — | — | — |
| Bladder | 1 | 0.22 | 0.03 to 1.54 | 0 | — | — | 1 | 0.77 | 0.11 to 5.45 |
| Kidney and other urinary organs | 3 | 0.80 | 0.26 to 2.49 | 0 | — | — | 3 | 1.87 | 0.60 to 5.80 |
| Brain, nervous system | 2 | 2.30 | 0.57 to 9.18 | 0 | — | — | 2 | 3.28 | 0.82 to 13.13 |
| Thyroid | 5 | 2.35 | 0.98 to 5.66 | 0 | — | — | 5 | 2.09 | 0.87 to 5.01 |
| Malignant lymphoma | 13 | 3.13 | 1.82 to 5.39 | 3 | 2.90 | 0.93 to 8.98 | 10 | 3.89 | 2.09 to 7.22 |
| Leukemia | 1 | 0.54 | 0.08 to 3.83 | 0 | — | — | 1 | 0.90 | 0.13 to 6.41 |